Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 4/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30762757 | 1.00 | MAPK13 (0.39) | MAPK13MAPK12MAPK11MAPK14KRAS | |
| SCHEMBL30762794 | 0.92 | MAPK13 (0.38) | MAPK13MAPK12MAPK11MAPK14KRAS | |
| SCHEMBL21543288 | 0.92 | MAPK13 (0.38) | MAPK13MAPK12MAPK11MAPK14KRAS | |
| SCHEMBL21542783 | 0.89 | KRAS (0.38) | MAPK13MAPK12MAPK11MAPK14KRAS | |
| SCHEMBL29700725 | 0.89 | KRAS (0.38) | MAPK13MAPK12MAPK11MAPK14KRAS | |
| SCHEMBL30502011 | 0.85 | KRAS (0.35) | KRASTRPV1HAVCR2 | |
| SCHEMBL30502014 | 0.85 | KRAS (0.35) | KRASTRPV1HAVCR2 | |
| SCHEMBL21543106 | 0.84 | NLRP3 (0.36) | TRPV1PARP1HAVCR2PARP2 | |
| SCHEMBL30762695 | 0.84 | NLRP3 (0.36) | TRPV1PARP1HAVCR2PARP2 | |
| SCHEMBL21542680 | 0.83 | KRAS (0.39) | KRASTRPV1HAVCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3974429-A1 | PRECURSORS OF KRAS G12C INHIBITORS | Amgen Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3788038-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3630761-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | Amgen Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018217651-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAPK13 738/4885MAPK12 1154/4885MAPK11 705/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | MAPK13 962/4885MAPK12 1616/4885MAPK11 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.